Advances in the surgical treatment of colorectal liver metastases

Revista da Associacao Medica Brasileira

Volumn 57, Issue 2, 2011, Pages 215-222

  Coimbra, Felipe José Fernández ^a   Pires, Thiago Costa ^a   da Costa Junior, Wilson Luiz ^a   Diniz, Alessandro Landskron ^a   Ribeiro, Héber Salvador de Castro ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Abdominal neoplasms; Colorectal neoplasms; Colorectal surgery; Digestive system neoplasms; Hepatectomy; Liver neoplasms

Indexed keywords

EID: 79955712489     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0104-4230(11)70047-1     Document Type: Review

References (64)

1. Bouvier AM, Remontet L, Jougla E, Launay G, Grosclaude P, Velten M et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol. 2004;28:877-81.
2. Faivre J, Manfredi S, Bouvier AM. Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med. 2003;187:815-22; discussion 22-3.
3. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg. 1999;86:158-69.
4. Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 2004;4:909-17.
5. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg. 1979;189:496-502.
6. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fu-kuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg. 1999;86:332-7.
7. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al. Recurrence and outcomes following hepatic resection, radio-frequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-25; discussion 25-7.
8. Ercolani G, Grazi GL, Ravaioli M, Cescon M Gardini A, Varotti G et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch Surg. 2002;137:1187-92.
9. Adam R, Delvart V, Pascal G, Vallanu A, Castaing D, Azoulay D et al. Rescue surgery for unresectable colorectal liver metastases down-staged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-57; discussion 57-8.
10. Giacchetti S, Itzhaki M, Gruia G. Long-term survival of patients with unresectable colorectal cancer liver metastases following influsional chemotherapy with 5-fuorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663-9.
11. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Frigilia N et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fuorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933-9.
12. Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Loyer R, Ellis LM et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8:233-40.
13. Mosteller RD. Simplifed calculation of body-surface area. N Engl J Med. 1987;317:1098.
14. Busquets J, Pelaez N, Alonso S, Grande L. Te study of cavitation-al ultrasonically aspirated material during surgery for colorectal liver metastases as a new concept in resection margin. Ann Surg. 2006;244:634-5.
15. Choti MA. Chemotherapy-associated hepatotoxicity: do we need to be concerned? Ann Surg Oncol. 2009;16:2391-4.
16. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival afer resection of hepatic metas-tases from colorectal cancer in patients screened by positron emission tomography with F-18 fuorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-47; discussion 47-50.
17. Lubezky N, Metser U, Geva R, Nakache R, Shmuele E, Klausner JM et al. The role and limitations of 18-fuoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007;11:472-8.
18. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Irnagartinger G, Oberdorfer F et al. Fluorine-18-fuorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med. 1998;39:1197-202.
19. Carnaghi C, Tronconi MC, Rimassa L, Tondulli L, Zuradelli M, Ro-dari M et al. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Nucl Med Rev Cent East Eur. 2007;10:12-5.
20. Angliviel B, Benoist S, Penna C, El Hajjam M, Chagnon S, Julie C et al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol. 2009;16:1247-53.
21. Benoist S, Brouquet A, Penna C, Angliviel B, Benoist S. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939-45.
22. Cohen M P, Machado MA, Herman P. Imapcto da ultrasonografa intra-operatória nas cirurgias para ressecção de metástases hepáti-cas. Arq Gastroenterol. 2005;42:206-12.
23. Lee WS, Kim MJ, Yun SH, Chung HK, Lee WY, Yun HR et al. Risk factor stratifcation after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg. 2008;393:13-9.
24. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Adres A, Muratore A et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg. 2006;10:86-94.
25. Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey JN. Total and segmental liver volume variations: implications for liver surgery. Surgery 2004;135:404-10.
26. Vauthey JN, Chaoui A, Do KA, Bilimori MM, Hicks M, Alsfassie G et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000;127:512-9.
27. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208-17.
28. Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness--study in 26 patients. Radiology. 2003;227:251-60.
29. Elias D, Lasser P, Rougier P, Ducreux M, Bognel C, Roche A. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg. 1995;180:213-9.
30. Bismuth H, Adam R, Levi F, Farabos C, Waltcher F, Castaing D et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-20; discussion 20-2.
31. Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg. 1999;86:784-8.
32. Giacchetti S, Perpoint B, Zidani R, Le Bain N, Fagguiolo R, Focan C et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-47.
33. Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M. A multicenter evaluation of intensified, ambulatory, chronomodu-lated chemotherapy with oxaliplatin, 5-fluorouracil, and leucov-orin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999;85:2532-40.
34. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Brummer PD, Brienza A, Adam R et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 1996;14:2950-8.
35. Levi F, Misset JL, Brienza S, Metzger G, Itzakhi M, Caussanel JP, et al. A chronopharmacologic phase II clinical trial with 5-fluo-rouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.
36. Kohne CH, Van Cutsem E, Wils J, Bokemeyer C, El Serafi M, Lutz MP et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005;23:4856-65.
37. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Kar-asek P et al. Irinotecan combined with fuorouracil compared with fuorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-7.
38. Saltz LB, Cox JV, Blanke C, Rosen LS, Moore MH, Maroun JA et al. Irinotecan plus fuorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-14.
39. Tournigand C, Andre T, Achille E, Lledo G, Fresh M, Mery-Mignaro D et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-37.
40. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20:4006-14.
41. Adam R, Avisar E, Ariche A. Five-year survival following hepatic resection afer neoadjuvant therapy for nonresectable colorectal. Ann Surg. Oncol. 2001;8:347-53.
42. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
43. August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer. Cancer 1985;55:1490-4.
44. Kokudo N, Sato T, Seki M, Ohta H, Azekura K, Ueno M et al. Hepatic lymph node involvement in resected cases of liver metastases from colorectal cancer. Dis Colon Rectum. 1999;42:1285-90; discussion 90-1.
45. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand I, Ranstam J et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73:727-31.
46. Jaeck D, Nakano H, Bachellier P, Inoue K, Weber C, Oussoultzoglou E et al. Signifcance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol. 2002;9:430-8.
47. Adam R, de Haas RJ, Wicherts DA, Aloia TA, Delvart V, Azoulay D et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol. 2008;26:3672-80.
48. Ashley AC, Deschamps C, Alberts SR. Impact of prognostic factors on clinical outcome afer resection of colorectal pulmonary metasta-ses. Clin Colorectal Cancer 2006;6:32-7.
49. Carpizo DR, DAngelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol. 2009;10:801-9.
50. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-63.
51. Carpizo DR, DAngelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol. 2009;16:2411-21.
52. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011-9.
53. Carmignani C P, Ortega-Perez G, Sugarbaker PH. The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol. 2004;30:391-8.
54. Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol. 2006;32:632-6.
55. Choti MA, Sitzmann J V, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulik RD et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-66.
56. Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veihan LA et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008;248:994-1005.
57. Martin R, Paty P, Fong Y, Grace A, Cohen A, De Matteo R et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. 2003;197:233-41; discussion 41-2.
58. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribeiro D, Assumpção L et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14:3481-91.
59. Brouquet A, Mortenson MM, Vauthey JN, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934-41.
60. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872-8.
61. Poultsides GA, Servais EL, Saltz LB, Patil S, Kameny NE, Guillem JG et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379-84.
62. Tebbutt NC, Norman AR, Cunningham D, Andreyev J. Intestinal complications afer chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568-73.
63. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-61; discussion 61-4.
64. Herman P, Machado MAC, Diniz AL, Coimbra FJF, Sallum RA, Montagnini AL. Surgical treatment of colorectal cancer hepatic me-tastases; experience of A. C. Camargo Cancer Hospital - São Paulo. Appl Cancer Res. 2006;26:88-93.